Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1414P - Helicobacter pylori infection is associated with clinical benefits of anti-PD-1/PD-L1-based therapies in advanced gastric/esophagogastric junction cancer: A real world multicenter observational study

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Gastric Cancer

Presenters

Qing Wei

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

Q. Wei1, C. Qi2, W. Guan3, X. Zhang3, X. Zhang4

Author affiliations

  • 1 Medical Oncology, Zhejiang Cancer Hospital, 311201 - Hangzhou/CN
  • 2 Department Of Gi Oncology, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 3 Medical Oncology, State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, CN., 510060 - Guangzhou/CN
  • 4 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education), Peking University Cancer Hospital and Institute, Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1414P

Background

Anti-PD-1/PD-L1-based therapy is the standard of care for patients with advanced gastric cancer or esophagogastric junction cancer. Helicobacter pylori (H. pylori, Hp) chronic infection in the stomach mucosa was the major cause of most gastric cancers, and there is a lack of data regarding the association between the efficacy of ICIs and H. pylori infection. We therefore perform a retrospective multicenter study to address this clinically relevant issue.

Methods

Gastric cancer or esophagogastric junction cancer patients who had Hp status results before ICI treatment from January 2016 through July 2020 at our institutes (Beijing Cancer Hospital, Zhejiang Cancer Hospital, or Sun Yat-sen University Cancer Center) were retrospectively reviewed. The patients received regimens including anti-PD-1/PD-L1 mono-therapy, or anti-PD-1/PD-L1 in combination with chemotherapy or anti-angiogenic/ tyrosine kinase inhibitors (TKI). Parameters including age, gender, primary site, differentiation, MSI status, PD-L1, metastastic sites, regimens etc., were included in the analysis.

Results

Of 120 patients, the 55 (45.8%) who tested positive for H. pylori were more likely to have MSI-H tumors (P = 0.016). H. pylori positivity was associated with longer PFS (P = 0.004) and OS (P = 0.013) within the entire cohort regardless of therapeutic modalities. The Hp infection was independently correlated with longer PFS (P = 0.008) and OS (P = 0.005) in the multivariate analysis. In patients receiving ICI monotherapy, H. pylori infection was significantly associated with better survival than H. pylori-negative patients in both PFS (P = 0.023) and OS (P = 0.002). In patients who received ICIs as the first-line therapy, H. pylori was associated with longer PFS (P = 0.003) and a trend of longer OS (P = 0.022).

Conclusions

Although Patients with vs. without H. pylori infection demonstrated distinct clinicopathologic features, H. pylori infection was still independently associated with favorable survival outcomes after the adjustment for multiple variables. Underlying molecular and cellular mechanisms remain elusive and warrant further study.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Qing Wei.

Funding

Zhejiang Natural Science Funding No.LQ21H160005.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.